LRRK2 and Parkinson disease: A phase I trial is underway to assess the safety, tolerability, and pharmacokinetics of intrathecal administration of an ASO called BIIB094 that targets LRRK2 mRNA expression in patients with PD (clinicaltrials.gov, NCT03976349).